Cargando…

Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors

Detalles Bibliográficos
Autores principales:	Suzuki, Tomotaka, Fukuhara, Suguru, Nomoto, Junko, Yamashita, Satoshi, Maeshima, Akiko (Miyagi), Ito, Yuta, Hatta, Shunsuke, Yuda, Sayako, Makita, Shinichi, Munakata, Wataru, Suzuki, Tatsuya, Maruyama, Dai, Taniguchi, Hirokazu, Ushijima, Toshikazu, Izutsu, Koji, Tobinai, Kensei, Kobayashi, Yukio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849574/ https://www.ncbi.nlm.nih.gov/pubmed/32336683 http://dx.doi.org/10.3324/haematol.2019.235598

Ejemplares similares

Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
por: Suzuki, Tomotaka, et al.
Publicado: (2021)

The role of local radiotherapy following rituximab‐containing chemotherapy in patients with transformed indolent B‐cell lymphoma
por: Nozaki, Kenji, et al.
Publicado: (2020)

Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab
por: Ito, Yuta, et al.
Publicado: (2018)

Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era
por: Yuda, Sayako, et al.
Publicado: (2016)

Transformation Scoring System (TSS): A new assessment index for clinical transformation of follicular lymphoma
por: Shichijo, Takafumi, et al.
Publicado: (2020)

Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review
por: Makita, Shinichi, et al.
Publicado: (2018)

Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin
por: Nakai, Ritsuko, et al.
Publicado: (2019)

Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome
por: Makita, Shinichi, et al.
Publicado: (2017)

FUS-ERG gene fusion in isolated myeloid sarcoma showing uncommon clinical features
por: Ueda, Ryosuke, et al.
Publicado: (2016)

Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma
por: Saito, H, et al.
Publicado: (2015)

Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma
por: Saito, H, et al.
Publicado: (2017)

The outcome of watchful waiting in patients with previously treated follicular lymphoma
por: Fujino, Takahiro, et al.
Publicado: (2022)

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma
por: Munakata, Wataru, et al.
Publicado: (2021)

Disseminated herpes zoster infection initially presenting with abdominal pain in patients with lymphoma undergoing conventional chemotherapy: A report of three cases
por: Okuma, Hitomi Sumiyoshi, et al.
Publicado: (2016)

Phase I study of tirabrutinib (ONO‐4059/GS‐4059) in patients with relapsed or refractory B‐cell malignancies in Japan
por: Munakata, Wataru, et al.
Publicado: (2019)

Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies
por: Munakata, Wataru, et al.
Publicado: (2022)

Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma
por: Nomoto, Junko, et al.
Publicado: (2012)

The role of surveillance computed tomography in patients with follicular lymphoma
por: Hatta, Shunsuke, et al.
Publicado: (2022)

Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study
por: Izutsu, Koji, et al.
Publicado: (2021)

Impact of the double expression of MYC and BCL2 on outcomes of localized primary gastric diffuse large B-cell lymphoma patients in the rituximab era
por: Kawajiri, A, et al.
Publicado: (2016)

Late relapse of cutaneous larva migrans
por: Dam Larsen, Fredrikke, et al.
Publicado: (2023)

A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia
por: Izutsu, Koji, et al.
Publicado: (2020)

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2016)

Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study
por: Kim, Won-Seog, et al.
Publicado: (2023)

Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
por: Kato, Koji, et al.
Publicado: (2021)

Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study
por: Iida, Shinsuke, et al.
Publicado: (2019)

A Case of Late Relapse in Typhoid Fever
por: Sivasankaran, V.
Publicado: (1940)

Late-Relapsing Hepatitis after Yellow Fever
por: Rezende, Izabela Maurício, et al.
Publicado: (2020)

Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
por: Maruyama, Dai, et al.
Publicado: (2020)

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
por: Watanabe, Takashi, et al.
Publicado: (2016)

Safety and effectiveness of mogamulizumab in relapsed or refractory adult T‐cell leukemia‐lymphoma
por: Ishitsuka, Kenji, et al.
Publicado: (2019)

COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma
por: Hosoba, Rika, et al.
Publicado: (2020)

Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas
por: Gaudio, Francesco, et al.
Publicado: (2011)

Surgical interventions for late ocular complications of relapsing polychondritis
por: He, Yuan, et al.
Publicado: (2016)

Testicular plasmocytoma as an unsual late relapse of multiple myeloma
por: Karray, Omar, et al.
Publicado: (2020)

Oral histone deacetylase inhibitor tucidinostat (HBI‐8000) in patients with relapsed or refractory adult T‐cell leukemia/lymphoma: Phase IIb results
por: Utsunomiya, Atae, et al.
Publicado: (2022)

Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma
por: Negoro, Eiju, et al.
Publicado: (2023)

Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies
por: Ogura, Michinori, et al.
Publicado: (2015)

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma
por: Izutsu, Koji, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_310la2vjfq41b37fgahv75im9r